Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Expert Argues Against Smokescreen on E-cigarette Research

By Drug Discovery Trends Editor | June 10, 2015

Until e-cigarettes are approved as medicines, smokers must obtain them from the black market. Source: University of QueenslandA leading Australian substance abuse expert is pleading for moderation in policies on e-cigarettes.

The University of Queensland’s Professor Wayne Hall said current law on electronic nicotine delivery systems placed researchers – and people who wanted to use e-cigarettes to quit smoking – in a difficult situation.

E-cigarettes containing nicotine cannot legally be sold in Australia.

”We should not have to choose between banning e-cigarettes completely and selling them alongside children’s candy,” Professor Hall said.

Professor Hall is an advisor to the World Health Organization and the director of UQ’s Centre for Youth Substance Abuse Research.

“We are told e-cigarettes will only be available to smokers as medicinal products to stop them smoking if clinical trials show them to be safe and effective.

“However, regulation as medicines may not be the best regulatory model and, until the products are approved as medicines, smokers must obtain them from the black market.

“Effectively, we are treating e-cigarettes like heroin or cocaine, and stifling any real research on their effectiveness.”

Such is debate on the topic, Professor Hall’s paper – Ethical issues raised by a ban on the sale of electronic nicotine devices — has met diverse reactions from around the world before its official publication.

Professor Hall and UQ collaborators Dr Coral Gartner and Dr Cynthia Forlini said those who recommended legalizing e-cigarettes were often portrayed as “in the pay of the tobacco industry”.

But he said this, and other forms of ad hominem argument, prevented a better understanding of ways of combating one of the world’s greatest causes of preventable death.

“A policy that bans a less harmful form of nicotine while still allowing the sale of cigarettes is inconsistent,” Professor Hall said.

“Laws are giving much higher priority to the interests of hypothetical smokers (who could take up smoking via e-cigarettes) at the expense of current, especially addicted, smokers.

“I do not advocate laissez faire, but rather closely-regulated e-cigarette sales for current smokers as a step towards an increased regulation of the most harmful tobacco products – cigarettes.

“If research proves e-cigarettes are much safer than cigarettes and are an acceptable substitute, we would have a strong case for removing cigarettes from convenience stores and supermarkets.”


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE